HOME
Our Mission:
BCG ONCOLOGY is developing novel cancer drugs that have better efficacy and lower side effects than existing cancer chemotherapy drugs.
Drugs:
Our lead drug, BCG-MTX is a conjugate of the effective chemotherapy drug methotrexate to a targeting protein. BCG-MTX was 15-times more effective than methotrexate in animal studies, and with much lower side effects. It has completed a Phase 1 study in advanced solid tumors and was effective even as a single agent in persons with heavily pre-treated advanced tumors that had progressed on approved drugs. And it had extremely low side effects, with no decrease in blood cell counts, unlike methotrexate and all chemotherapy drugs.
https://clinicaltrials.gov/ct2/show/NCT02045368. https://www.ncbi.nlm.nih.gov/pubmed/31633515BCG-MTX is now in a second clinical trial at the Mayo Clinic in the blood cancer myelodysplastic syndrome (MDS). Early results again show very promising efficacy
and low side effects.
We also have a further pipeline of targeted cancer drugs.
About Us:
BCG Oncology, P.C. is committed to advancing bladder cancer research and offers opportunities for patients to participate in clinical trials for new treatments. Dr. Lamm, who has authored numerous peer-reviewed articles, regularly answers patients' questions about bladder cancer, kidney cancer, and other genitourinary cancers. With a focus on providing comprehensive and up-to-date information, BCG Oncology, P.C. strives to support patients in their journey towards better health and offers a range of resources, including urology news feeds and informative articles on symptoms, treatment, prevention, and research..